Compare IHG & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHG | NBIX |
|---|---|---|
| Founded | 1777 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.4B |
| IPO Year | N/A | 1996 |
| Metric | IHG | NBIX |
|---|---|---|
| Price | $134.45 | $155.41 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 18 |
| Target Price | N/A | ★ $172.33 |
| AVG Volume (30 Days) | 149.3K | ★ 963.8K |
| Earning Date | 01-01-0001 | 10-28-2025 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | ★ 21.99 | 12.44 |
| EPS | ★ 4.70 | 4.19 |
| Revenue | ★ $5,120,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $6.21 | $18.01 |
| P/E Ratio | ★ $28.68 | $36.68 |
| Revenue Growth | ★ 33.89 | 19.61 |
| 52 Week Low | $94.78 | $84.23 |
| 52 Week High | $137.73 | $157.67 |
| Indicator | IHG | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.92 | 64.98 |
| Support Level | $132.36 | $150.26 |
| Resistance Level | $137.73 | $154.35 |
| Average True Range (ATR) | 2.03 | 4.16 |
| MACD | 0.29 | 1.08 |
| Stochastic Oscillator | 73.45 | 94.02 |
InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.